Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 1.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.65 | 1.36 |
NAV | ₹148.56 | ₹199.04 |
Fund Started | 29 Sep 2006 | 07 May 2007 |
Fund Size | ₹19162.03 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1% if redeemed less than 12 months | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 2.79% | 7.45% |
3 Year | 19.27% | 26.44% |
5 Year | 19.04% | 29.43% |
1 Year
3 Year
5 Year
Equity | 95.31% | 93.60% |
Cash | 4.69% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Coforge Ltd. | 4.10% |
Ipca Laboratories Ltd. | 3.24% |
Supreme Industries Ltd. | 2.75% |
L&T Finance Ltd. | 2.70% |
Coromandel International Ltd. | 2.68% |
Fortis Healthcare Ltd. | 2.61% |
Voltas Ltd. | 2.57% |
Power Finance Corporation Ltd. | 2.48% |
Jindal Steel Ltd. | 2.43% |
Max Financial Services Ltd. | 2.42% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Jay Kothari | Chirag Setalvad |
Start Date | 07 Mar 2024 | 28 Jun 2014 |
Name
Start Date
Description | The scheme aims to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of midcap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 29 Sep 2006 | 07 May 2007 |
Description
Launch Date